Your Diet Is Manufacturing Your Pain | The Pained Brain, Chapter 5

NSAID cardiovascular risk · Chronic pain

NSAID Cardiovascular Risk in Chronic Pain: Who to Measure and Why

Measure daily or near-daily NSAID users with chronic pain, especially those with diabetes, hypertension, kidney disease or a metabolic phenotype. Pooled trials put major vascular events up with coxibs and diclofenac, heart failure risk roughly doubled across the class, and chronic use carried a 1.50 hazard for chronic kidney disease.

Chronic NSAID users are an identifiable population carrying measurable vascular and renal exposure, and most of them are never assessed for it.

NSAID cardiovascular risk is well characterized in trials and seldom measured in the individual taking the drug. The daily ibuprofen or naproxen user with chronic musculoskeletal pain appears on a medication list, receives a renewal, and rarely receives a vascular, renal or metabolic assessment tied to that exposure. The video above is Chapter 5 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, which argues that the prostaglandin pathway these drugs block is supplied by the omega-6 content of the diet. For a screening practice, that argument reduces to two questions: which chronic users should be measured, and what a finding changes.

How much do NSAIDs raise cardiovascular risk?

The Coxib and traditional NSAID Trialists’ Collaboration pooled individual data from 280 placebo-controlled trials and 124,513 participants. Major vascular events rose with coxibs (RR 1.37) and diclofenac (RR 1.41), roughly three additional events per 1,000 patients treated for a year, one of them fatal. Naproxen was the vascular exception (RR 0.93). Heart failure risk roughly doubled across the class, and upper gastrointestinal complications rose 3.97-fold on ibuprofen and 4.22-fold on naproxen. Those trials used high doses in selected, often high-risk populations.

The signal is not confined to long courses. A Bayesian individual-patient meta-analysis of 446,763 people found odds ratios for acute myocardial infarction of 1.48 for ibuprofen, 1.50 for diclofenac and 1.53 for naproxen within one to seven days of use, dose-related and front-loaded rather than accumulating with duration. On the renal side, 40 studies covering 1,757,118 participants gave chronic use a pooled hazard of 1.50 for chronic kidney disease, 1.67 with pre-existing kidney disease and 1.35 in diabetes or hypertension. Confounding by indication is plausible in both datasets; it does not erase them.

Patient behavior widens the gap between label and exposure. In a one-week diary study of 1,326 American ibuprofen users, 37 percent also took a non-ibuprofen NSAID and 11 percent exceeded the daily ibuprofen limit, with ongoing pain among the associated characteristics.

How much do NSAIDs actually help spinal pain?

Most of us, myself included, were trained to renew the anti-inflammatory and treat the diet as somebody else’s department. The efficacy data in spinal pain do not support that reflex. Across 35 placebo-controlled trials, only 3 of 14 comparisons cleared a ten-point minimum worthwhile difference, the number needed to treat was 6, and gastrointestinal adverse events were already 2.5 times as common in trials with a median duration of 7 days. The authors concluded that no simple analgesic gives clinically important relief for spinal pain, not that NSAIDs are useless. For the physician deciding whether to measure, the relevant point is that the risk-benefit balance in long-term users is close enough for patient-level data to carry real weight.

Is a normal CRP enough to clear a chronic pain patient?

A common shortcut is to check C-reactive protein and move on. The evidence behind that shortcut was generated in the wrong population. The founding systematic review of dietary linoleic acid and inflammatory markers covered 15 randomized trials in healthy adults. A later pooling of 30 trials and 1,377 participants found a CRP effect of SMD 0.09, indistinguishable from zero, with a subgroup hint of a rise at the largest intake increases. Obese, insulin-resistant and chronic pain patients were largely absent.

In a crossover of 39 abdominally obese adults given seven weeks of marine omega-3 and seven of linoleic acid, circulating markers did not differ between treatments, yet adipose biopsies showed 334 differentially expressed genes after the omega-6 period, with inflammatory pathways up-regulated. Red-cell composition tells a parallel story: in 605 adults with chronic pain conditions, a higher arachidonic acid to EPA-plus-DHA ratio tracked higher pain intensity, cross-sectionally. The practical inference is that a normal CRP in a metabolically burdened pain patient does not clear the terrain. The population baseline is poor: 97.6 percent of US adults have a red-cell omega-3 index below 8 percent, and under 12.2 percent of US adults were metabolically healthy on NHANES 2009–2016, under 7 percent on the tighter post-2021 criteria.

Who to measure

A workable selection rule for primary care, pain, cardiology or geriatric practice starts from the medication list rather than from symptoms:

Daily or near-daily NSAID use beyond a short course, prescribed or over the counter.
Chronic NSAID use with diabetes, hypertension or known kidney disease, the subgroups carrying the higher renal hazards.
Chronic pain with a metabolic phenotype: central adiposity, dysglycemia, or the thin-outside, inflamed-inside pattern that body weight conceals.
Long-term use of the same agent without a documented reassessment.

Arterial stiffness and endothelial function assesses large-artery rigidity and the vessel lining’s capacity to dilate. Its relevance here is supported indirectly, including a cross-sectional association in 346 nonsmokers between a urinary acrolein metabolite, a product of heated polyunsaturated oil among other sources, and worse endothelial function. Laboratory panels define glycemic and insulin status alongside the renal markers the prescriber already follows. Bioimpedance body composition separates the lean and fat compartments that BMI conflates. Measura [Cardiometabolic and Autonomic Health Analysis] returns findings to the ordering physician; it does not diagnose disease on its own or manage the medication.

What a finding changes

An abnormal vascular or metabolic result does not dictate a prescribing decision. It improves the one the treating physician makes: the risk side of the NSAID discussion gains an individual measurement instead of a population estimate, the decision about agent, dose and duration becomes documented, and patients whose kidney function deserves closer follow-up are flagged. It also opens the upstream conversation Chapter 5 is really about, correcting the lipid profile. In the book’s protocol that means measuring the red-cell omega-3 index against a target above 8 percent, removing seed oils, adding EPA and DHA, and retesting at about five months, since red-cell content took roughly that long to equilibrate in a dose-response trial of 115 healthy adults. Food-based trials support the direction: in 182 adults with migraine, a high omega-3, low omega-6 diet produced 4.0 fewer headache days a month than control, although the primary quality-of-life endpoint did not reach significance.

Building it into workflow

The trigger already sits in the record. A standing order keyed to chronic NSAID use on the medication list makes the screen reproducible rather than dependent on who is in clinic that day. The annual wellness visit medication review is a natural place for it to fire. Results belong in structured fields the next prescriber will see, which getting results into the record covers, and where a practice reports cardiovascular or diabetes-related quality measures, the same data support documentation under MIPS and quality reporting. The patient-facing account of the same evidence is the patient article on seed oils and inflammation; the study-by-study appraisal is on the Chapter 5 book companion page; and the glycation problem that follows is in hand and shoulder diagnoses as dysglycemia screening triggers.

Frequently asked questions

Is naproxen the safer choice for patients with cardiovascular risk?

For major vascular events, naproxen was the exception in the individual-participant meta-analysis, at RR 0.93. It was not an exception for upper gastrointestinal complications, which rose 4.22-fold, and the short-term myocardial infarction analysis still found odds of 1.53 within the first week of use. Heart failure risk roughly doubled across NSAIDs. Agent selection narrows the risk; it does not remove it. Clinical rationale.

Does a normal CRP mean dietary omega-6 is not a problem for this patient?

Not in a metabolically burdened patient. The trials showing no CRP effect were largely conducted in healthy adults over weeks. In abdominally obese adults, seven weeks of linoleic acid left circulating markers unchanged while adipose tissue showed inflammatory gene up-regulation. CRP reports the blood compartment; the argument concerns tissue and membrane composition, which it does not see. Interpreting the report.

Which chronic NSAID users should be prioritized for vascular testing?

Start with daily users who also carry diabetes, hypertension or kidney disease, since those subgroups showed higher renal hazards, and with patients on diclofenac or coxibs, which carried the larger vascular signals. Ask directly about over-the-counter products taken on top of a prescription: in a diary study, more than a third of ibuprofen users also took another NSAID. Specialty applications.

When should an omega-3 index be rechecked after a dietary change?

At around five months. In a randomized dose-response trial of 115 healthy adults, red-cell omega-3 content took approximately that long to reach its new level, and dose alone explained 68 percent of the variability. An earlier recheck risks reading an incomplete transition as failure. Supplement pain trials also showed effects growing over time, from SMD 0.27 at one month to 0.83 at six. Chronic care and between-visit monitoring.

How should the screen be documented?

Record the trigger, the indication for the NSAID, the measurements obtained and the resulting decision about agent, dose or duration in structured fields. That converts a routine renewal into a documented reassessment and gives the next clinician a baseline to compare against. Quality programs reward exactly this kind of reproducible, measured process. Getting diagnostic results into the chart.

Which NSAID has the highest cardiovascular risk?

In pooled data from 280 placebo-controlled trials, diclofenac (RR 1.41) and the coxibs (RR 1.37) carried the largest rise in major vascular events, while naproxen did not (RR 0.93). Heart failure risk roughly doubled across the class, and within the first week of use the odds of a heart attack rose for ibuprofen, diclofenac and naproxen alike, at 1.48 to 1.53.

Is it harmful to take ibuprofen every day?

Daily use is the exposure this page is about. Chronic NSAID use carried a 1.50 hazard for chronic kidney disease, higher with existing kidney disease, and heart attack odds rose within days of starting. Daily users often take more than they realize: in a one-week diary study, 37 percent of ibuprofen users also took another NSAID and 11 percent exceeded the daily limit. Review dose and duration with your prescriber.

See how the protocol fits your practice

Learn how Measura testing can be added to your screening workflow for patients on long-term anti-inflammatory therapy, from standing orders to reporting.

Send a message

4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

References

Coxib and traditional NSAID Trialists’ (CNT) Collaboration (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. The Lancet, 382(9894), 769-779. https://doi.org/10.1016/S0140-6736(13)60900-9
Bally, M., Dendukuri, N., Rich, B., Nadeau, L., Helin-Salmivaara, A., Garbe, E., & Brophy, J. M. (2017). Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ, 357, j1909. https://doi.org/10.1136/bmj.j1909
Soliman, S., Ahmed, R. M., Ahmed, M. M., Attia, A., & Soliman, A. R. (2025). Non-steroidal anti-inflammatory drugs: what is the actual risk of chronic kidney disease? A systematic review and meta-analysis. Romanian Journal of Internal Medicine, 63(1), 3-27. https://doi.org/10.2478/rjim-2024-0029
Kaufman, D. W., Kelly, J. P., Battista, D. R., Malone, M. K., Weinstein, R. B., & Shiffman, S. (2018). Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users. Pharmacoepidemiology and Drug Safety, 27(3), 322-331. https://doi.org/10.1002/pds.4391
Machado, G. C., Maher, C. G., Ferreira, P. H., Day, R. O., Pinheiro, M. B., & Ferreira, M. L. (2017). Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 76(7), 1269-1278. https://doi.org/10.1136/annrheumdis-2016-210597
Su, H., Liu, R., Chang, M., Huang, J., & Wang, X. (2017). Dietary linoleic acid intake and blood inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Food & Function, 8(9), 3091-3103. https://doi.org/10.1039/c7fo00433h
Grytten, E., Laupsa-Borge, J., Cetin, K., Bohov, P., Nordrehaug, J. E., Skorve, J., Berge, R. K., Strand, E., Bjørndal, B., Nygård, O. K., Rostrup, E., Mellgren, G., & Dankel, S. N. (2025). Inflammatory markers after supplementation with marine n-3 or plant n-6 PUFAs: A randomized double-blind crossover study. Journal of Lipid Research, 66(4), 100770. https://doi.org/10.1016/j.jlr.2025.100770
Flock, M. R., Skulas-Ray, A. C., Harris, W. S., Etherton, T. D., Fleming, J. A., & Kris-Etherton, P. M. (2013). Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial. Journal of the American Heart Association, 2(6), e000513. https://doi.org/10.1161/JAHA.113.000513
McGraw, K. E., Riggs, D. W., Rai, S., Navas-Acien, A., Xie, Z., Lorkiewicz, P., Lynch, J., Zafar, N., Krishnasamy, S., Taylor, K. C., Conklin, D. J., DeFilippis, A. P., Srivastava, S., & Bhatnagar, A. (2021). Exposure to volatile organic compounds – acrolein, 1,3-butadiene, and crotonaldehyde – is associated with vascular dysfunction. Environmental Research, 196, 110903. https://doi.org/10.1016/j.envres.2021.110903
Ramsden, C. E., Zamora, D., Faurot, K. R., MacIntosh, B., Horowitz, M., Keyes, G. S., Yuan, Z.-X., Miller, V., Lynch, C., Honvoh, G., Park, J., Levy, R., Domenichiello, A. F., Johnston, A., Majchrzak-Hong, S., Hibbeln, J. R., Barrow, D. A., Loewke, J., Davis, J. M., … Mann, J. D. (2021). Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ, 374, n1448. https://doi.org/10.1136/bmj.n1448